Pharmaceutical ETFs XPH and PJP compared by cost and strategy

A comparison of two prominent pharmaceutical ETFs, the State Street SPDR S&P Pharmaceuticals ETF (XPH) and the Invesco Pharmaceuticals ETF (PJP), highlights different strategic approaches to the sector.

XPH offers broader sector exposure with a lower annual expense ratio of 0.35%. In contrast, PJP provides a more concentrated, low-volatility approach focusing on 29 established healthcare companies. PJP’s largest holdings include Abbott Laboratories, AbbVie, and Amgen. While XPH is more cost-effective, PJP offers a slightly higher dividend yield of 0.8% compared to XPH’s 0.5%.